- Home
- MCRB vs CBAT Comparison
MCRB vs CBAT Comparison
Compare MCRB & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- CBAT
- Stock Information
- Founded
- MCRB 2010
- CBAT 1999
- Country
- MCRB United States
- CBAT China
- Employees
- MCRB N/A
- CBAT N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- MCRB Health Care
- CBAT Miscellaneous
- Exchange
- MCRB Nasdaq
- CBAT Nasdaq
- Market Cap
- MCRB 103.7M
- CBAT 102.5M
- IPO Year
- MCRB 2015
- CBAT N/A
- Fundamental
- Price
- MCRB $12.09
- CBAT $1.07
- Analyst Decision
- MCRB Hold
- CBAT
- Analyst Count
- MCRB 4
- CBAT 0
- Target Price
- MCRB $73.67
- CBAT N/A
- AVG Volume (30 Days)
- MCRB 109.0K
- CBAT 250.6K
- Earning Date
- MCRB 08-12-2025
- CBAT 08-08-2025
- Dividend Yield
- MCRB N/A
- CBAT N/A
- EPS Growth
- MCRB N/A
- CBAT N/A
- EPS
- MCRB 8.98
- CBAT 0.00
- Revenue
- MCRB N/A
- CBAT $152,731,078.00
- Revenue This Year
- MCRB N/A
- CBAT $28.79
- Revenue Next Year
- MCRB N/A
- CBAT $36.77
- P/E Ratio
- MCRB $1.50
- CBAT $257.07
- Revenue Growth
- MCRB N/A
- CBAT N/A
- 52 Week Low
- MCRB $6.53
- CBAT $0.57
- 52 Week High
- MCRB $30.60
- CBAT $1.45
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- CBAT 45.31
- Support Level
- MCRB $10.67
- CBAT $1.13
- Resistance Level
- MCRB $12.84
- CBAT $1.21
- Average True Range (ATR)
- MCRB 1.09
- CBAT 0.05
- MACD
- MCRB 0.34
- CBAT -0.02
- Stochastic Oscillator
- MCRB 85.98
- CBAT 7.86
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.